insights_auto
Outlook: 40.0% bullish·10.0% bearish
Go to analysischevron_right
ALNY:NASDAQ
Alnylam Pharmaceuticals, Inc.
223,82 $
arrow_downward
-1,41%(-3,20) 1D
223,82 $
0,00% (0,00)
bedtimeAfter hours
Closed: 13 հոկ, 16:00:01 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALNY...
Open
228,93 $
High
229,52 $
Low
221,56 $
Mkt. cap
29,95 մլրդ
Avg. vol.
1,46 մլն
Volume
1,12 մլն
P/E ratio
38,09
52-wk high
495,55 $
52-wk low
197,81 $
EPS
5,88 $
Beta
0,28
Shares outstanding
133,81 մլն
No. of employees
2 հզր
Open
228,93 $
High
229,52 $
Low
221,56 $
Mkt. cap
29,95 մլրդ
Avg. vol.
1,46 մլն
Volume
1,12 մլն
P/E ratio
38,09
52-wk high
495,55 $
52-wk low
197,81 $
EPS
5,88 $
Beta
0,28
Shares outstanding
133,81 մլն
No. of employees
2 հզր
News stories
From web sources and news partners
Benzinga
·
2 ժամ առաջ
If You Invested $1000 In Alnylam Pharmaceuticals Stock 15 Years Ago, You Would Have This Much Today
Investing.com Canada
·
15 ժամ առաջ
Form 4 Alnylam Pharmaceuticals Inc For: 13 October By Investing.com
The Globe and Mail
·
1 օր առաջ
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Solventum Corporation (SOLV)
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals, Inc.